Compare Medpace Holdings Inc (MEDP) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Ferrari NV — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Ferrari NV trades at $389.91 (market cap $67.35B). The key difference: Ferrari NV is far larger — about 4× Medpace Holdings Inc's market cap, and Ferrari NV pays a 1.09% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Ferrari NV for 126 Days on average.
| MEDP | RACE | |
|---|---|---|
Market Cap | $16.82B | $67.35B |
Volume | 223,093 | 390,618 |
Sector | Health | Consumer Cyclical |
52-Week High | $630.19 | $436.54 |
52-Week Low | $393.42 | $314.63 |
Typical Hold Time | 14 Days | 126 Days |
Enterprise Value | $16.44B | $69.22B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Ferrari (RACE) trades at $388.77, up 0.62% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $7.15 billion in 2025, and net income margin remains robust at 22.25%. The company is executing a share buyback program and expanding partnerships, such as with Rakuten effective 2027.
The outlook is positive given analyst consensus of $462.75 price target and 73.69% buy ratings. Risks include high valuation multiples and exposure to economic cycles. Institutional interest is rising, but technical indicators suggest near-term resistance at $390.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
